Regenxbio
RGNX
186 hedge funds and large institutions have $458M invested in Regenxbio in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 66 increasing their positions, 50 reducing their positions, and 25 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 50
20% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 25
3% more funds holding
Funds holding: 181 → 186 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.46% less ownership
Funds ownership: 88.82% → 88.36% (-0.46%)
11% less capital invested
Capital invested by funds: $512M → $458M (-$53.9M)
77% less call options, than puts
Call options by funds: $1.5M | Put options by funds: $6.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$6.9M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$3.96M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$3.94M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.82M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.08M |
| 2 |
JP Morgan Chase
New York
|
-$6.52M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$6.18M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.13M |
| 5 |
AG
Artal Group
Luxembourg
|
-$2.92M |
RGNX Hedge Fund Activity: Q3 2024 in Review
186 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2024, worth a combined $458M — down 11% from $512M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RGNX positions and 25 closed out — a net gain of 5 holders — while 66 added to existing stakes and 50 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $6.9M. The largest seller was Vanguard Group, cutting an estimated $9.08M.
- 186 institutional investors held Regenxbio (RGNX) as of Q3 2024, up from 181 in Q2 2024.
- Funds reported $458M of Regenxbio stock for Q3 2024, down 11% quarter-over-quarter.
- 30 funds opened new Regenxbio positions in Q3 2024 and 25 closed out, a net change of +5 holders.
- The largest Regenxbio buyer in Q3 2024 was ADAR1 Capital Management, an estimated $6.9M added.
- The largest Regenxbio seller in Q3 2024 was Vanguard Group, an estimated $9.08M sold.
Based on aggregated 13F filings for Q3 2024.